by Clinical Neuropsychologist Online | Thursday, August 20, 2026 | Dementia
Abstract Increasing evidence suggests that myelin dysfunction and oligodendrocyte pathology are active contributors to neurodegeneration. In Alzheimer’s disease (AD), the link between tau aggregation and myelin integrity remains unclear, despite the preferential...
by Clinical Neuropsychologist Online | Thursday, August 20, 2026 | Dementia
Abstract Mild cognitive impairment and dementia are underrecognized in primary care, contributing to delayed diagnosis and limited access to care. Growing research has focused on improving cognitive evaluation in primary care, including the development of digital...
by Clinical Neuropsychologist Online | Tuesday, August 18, 2026 | Dementia
Abstract INTRODUCTION Neuroimaging studies report associations of amyloid beta (Aβ) positron emission tomography (PET) with [18F](S)-(2-methylpyrid-5-yl)-6-[(3-fluoro-2-hydroxy)propoxy]quinoline ([18F]SMBT-1), a novel reactive astrogliosis surrogate radiotracer with...
by Clinical Neuropsychologist Online | Friday, August 14, 2026 | Dementia
Overview of the study design and analytical workflow. Plasma samples from cognitively unimpaired (CU) participants were analyzed to evaluate progression to symptomatic Alzheimer’s disease (AD), and additional analyses examined progression from mild cognitive...
by Clinical Neuropsychologist Online | Friday, August 14, 2026 | Dementia
Abstract INTRODUCTION Amyloid-lowering antibodies are associated with neuroanatomical volume changes. This study aims to disentangle the contributions of amyloid-related imaging abnormalities (ARIA) and amyloid clearance to these changes. METHODS Data from the...
